<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.</p>
David S. Hong, MD, deputy director of the department of investigational cancer therapeutics and associate vice president at The University of Texas MD Anderson Cancer Center, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer.
The phase I study led to a recommended phase II dose of 2 mg/kg every 3 weeks, according to Hong. This dose showed activity across a number of histologies, but in particular, showed promising results in this patient population with cervical cancer.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More